NFKB1 and inflammatory bowel disease: Although miR-155 and miR-126 have been demonstrated to promote intestinal inflammation in IBD by inhibiting the expression of NF-κB inhibitor IκBα [59, 60], they are not the miRNA targets in HPM treatment on Tianshu and Qihai of experimental CD rats, indicating that HPM has specificity in terms of gene regulation.